BOTHELL, Wash.--(BUSINESS WIRE)--Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that a scientific paper co-authored by Ryo Kubota, M.D., Ph.D., chairman, president and chief executive officer of Acucela, has been published in Experimental Eye Research (Exp. Eye. Res. 2010, 91;153-61). The paper, “Visual Cycle Modulation in Neurovascular Retinopathy” was also co-authored by scientists from Children’s Hospital and Harvard Medical School in Boston and demonstrates for the first time the impact of treatment with a visual cycle modulator (VCM) on retinopathy in an immature eye.
